Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digital Mammography Firms Decry Clinical Trial Provisions In Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

Digital mammography systems are on the verge of being downclassified to 510(k) status, but imaging firms say the clinical trial requirements proposed in FDA's draft "special controls" guidance for the systems are costly, unnecessary and overly burdensome
Advertisement

Related Content

Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule
Digital Mammography Systems Are Now 510(k) Products – FDA Final Rule
Clinical Data Needed For Some Digital Mammography 510(k)s, Panel Says
Clinical Data Needed For Some Digital Mammography 510(k)s, Panel Says
Regulatory News In Brief
Regulatory News In Brief
FDA Reclassifications In Brief
FDA Reclassifications In Brief
Advertisement
UsernamePublicRestriction

Register

MT026533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel